Baliarda S.A. states that, even though the Internet is a global communication medium, the pharmaceutical industry is subject to specific regulations on each country. The page “Products” is destined to satisfy the need of health professionals for comprehensive information on the proper usage of medicines and shall not be construed as medical advice nor shall it delay medical consultation.
Baliarda S.A. advices to always consult a proper health professional.
The information contained in this page is the same prescribing information approved by the National Administration of Drugs, Food and Medical Devices (ANMAT).
COMPOSITION:
Each film-coated tablet contains:
Rivaroxaban 20 mg.
HOW SUPPLIED:
Boxes containing 30 film-coated tablets.
RIXATYL it is subject to an ANMAT-approved Risk Management Plan (RMP). For further information
please click this email address: farmacovigilancia@baliarda.com.ar.
COMPOSITION:
Each film-coated tablet contains:
Rivaroxaban 10 mg.
HOW SUPPLIED:
Boxes containing 15 and 30 film-coated tablets.
RIXATYL it is subject to an ANMAT-approved Risk Management Plan (RMP). For further information
please click this email address: farmacovigilancia@baliarda.com.ar.
COMPOSITION:
Each film-coated tablet contains:
Rivaroxaban 15 mg.
HOW SUPPLIED:
Boxes containing 30 film-coated tablets.
RIXATYL it is subject to an ANMAT-approved Risk Management Plan (RMP). For further information
please click this email address: farmacovigilancia@baliarda.com.ar.
COMPOSITION:
Each film-coated tablet contains:
Rivaroxaban 2.5 mg.
HOW SUPPLIED:
Boxes containing 60 film-coated tablets.
RIXATYL it is subject to an ANMAT-approved Risk Management Plan (RMP). For further information
please click this email address: farmacovigilancia@baliarda.com.ar.
